Hims vs Sequence 2026: GLP-1 Weight Loss Programs Compared

Head-to-Head Comparison Table

The following table compares Hims, Sequence, and Trimi across the factors that matter most for patients choosing a GLP-1 weight loss provider. All pricing reflects data observed in early 2026.

Pricing Analysis: How Each Platform Bills

Hims and Sequence (now WW Med+) both bill a membership fee separately from medication, and their pricing reflects genuinely different business models. GLP-1 therapy is not a one-month experiment, most patients need 6 to 12 months of continuous treatment to reach meaningful weight loss goals, and many continue maintenance dosing indefinitely. Monthly cost differences compound into thousands of dollars over a typical treatment course, making pricing analysis essential before committing.

In its March 2026 announcement, Hims listed its Weight Loss Membership at $39 for the first month, then auto-renewing at $149 per month, billed separately from medication, and said medication is not available without a membership. We could not confirm Hims' per-medication prices in October 2026, so check Hims' current weight-loss pricing page for medication costs.

As of October 2026, WeightWatchers lists WW Med+ (formerly Sequence) at $25 for the first month with a 12-month or 6-month plan, then $74 per month on the 12-month plan or $84 per month on the 6-month plan. Plans auto-renew unless canceled, and GLP-1 medication is billed separately.

At Trimi, compounded semaglutide costs $99 per month and compounded tirzepatide costs $125 per month on the annual plan, a 12-month commitment. There is no consultation fee, no enrollment fee, and no membership fee. A patient taking semaglutide for 12 months at Trimi pays $1,188 total. Compounded medications are not FDA-approved. For a broader cost comparison, see our guide to the cheapest GLP-1 options in 2026.

Medications and Access: What Each Platform Prescribes

Hims and WW Med+ (formerly Sequence) both prescribe FDA-approved brand-name versions of the two most clinically validated GLP-1 weight loss medications, semaglutide and tirzepatide, such as Wegovy and Zepbound. Compounded semaglutide and tirzepatide, which Trimi offers, are prepared per individual prescription by state-licensed pharmacies and are not FDA-approved.

In March and April 2026 announcements, Hims said its providers can prescribe Wegovy pills, Wegovy injections and Ozempic injections, and can send prescriptions for Zepbound vials, Zepbound KwikPen and Foundayo to the LillyDirect pharmacy. Its August 2026 earnings release says it also offers compounded GLP-1 access on a limited scale. Patients manage prescriptions, refills, and dose adjustments through the Hims app.

As of October 2026, WeightWatchers says WW Med+ (formerly Sequence) only prescribes FDA-approved medications. It says many medications are covered by insurance, that its insurance coordinators currently work only with commercial insurance plans, and that it also offers cash-pay options, including self-pay offers for the Wegovy pill and for Zepbound through LillyDirect.

Trimi offers both compounded semaglutide and compounded tirzepatide as core offerings with consistent availability. Because Trimi focuses specifically on metabolic health and GLP-1 therapy, medication supply continuity is a central operational priority rather than one product line among many. Patients who start with semaglutide and later want to transition to tirzepatide, or vice versa based on clinical response and tolerability, can do so seamlessly within the same platform and provider relationship. For patients interested in understanding the differences between these medications, our semaglutide and tirzepatide treatment pages detail mechanisms, dosing protocols, and expected outcomes.

Provider Experience: How Each Platform Delivers Care

The provider experience is where Hims and Sequence diverge most dramatically, and it represents the core trade-off patients must evaluate when choosing between these platforms. GLP-1 therapy involves dose titration decisions, side effect management, treatment duration planning, and ongoing clinical monitoring, all of which benefit from provider expertise and engagement. The question is how much that expertise is worth and whether it translates into measurably better outcomes for your specific clinical situation.

Hims operates primarily through an app-based asynchronous model. Patients complete an online health questionnaire, a provider reviews the submission, and if appropriate, a prescription is issued without a live consultation. This approach uses online care. The trade-off is limited clinical dialogue. When you have questions about managing Hims weight loss side effects like nausea, constipation, or injection site reactions, the asynchronous model can feel impersonal. Hims also operates across many health categories beyond weight loss.

As of October 2026, the program formerly known as Sequence is marketed as WW Med+, with medical services provided through WeightWatchers Clinic; check WeightWatchers' site for how visits and clinician follow-up work. For patients with Sequence-specific side effect concerns, ask how the program handles side-effect questions before enrolling.

Trimi's provider model is a third approach. Trimi providers focus exclusively on weight management and metabolic health, developing deep expertise in GLP-1 therapy through daily clinical practice in this specific area. Trimi's web and messaging-based system allows patients to communicate directly with their care team for dose questions, side effect guidance, and treatment adjustments without additional fees.

Clinical Evidence: Results Come from the Medication, Not the Brand

A critical point that sometimes gets obscured in provider comparisons: your weight loss outcomes are determined primarily by the medication, the dose, and your adherence to treatment, not which telehealth platform delivered the prescription. The clinical evidence supporting GLP-1 medications for weight loss is extensive, well-replicated, and platform-independent. Understanding this evidence helps patients make decisions based on data rather than marketing.

The STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity or overweight to semaglutide 2.4 mg weekly or placebo. Over 68 weeks, participants receiving semaglutide lost an average of 14.9 percent of their body weight compared to 2.4 percent in the placebo group. Additionally, 86.4 percent of semaglutide-treated participants achieved at least 5 percent weight loss, and 69.1 percent achieved at least 10 percent. This trial established semaglutide as one of the most effective pharmaceutical interventions for weight management, with efficacy far exceeding older weight loss medications and approaching results previously achievable only through bariatric surgery.

The SURMOUNT-1 trial, published by Jastreboff et al. in the New England Journal of Medicine in 2022, evaluated tirzepatide in 2,539 adults with obesity. The highest dose group (15 mg weekly) achieved an average weight reduction of 22.5 percent of body weight over 72 weeks, the largest average weight loss ever recorded in a pharmaceutical obesity trial. Even the lowest tirzepatide dose (5 mg) produced 15 percent average weight loss, comparable to the maximum semaglutide dose. Tirzepatide's dual mechanism as both a GIP and GLP-1 receptor agonist produces additive metabolic benefits that GLP-1 stimulation alone does not achieve.

These trial results describe the FDA-approved brand products that were studied. Compounded semaglutide and tirzepatide are prepared per individual prescription by state-licensed pharmacies and are not FDA-approved as drugs, so published brand trial data should not be read as a promise about any compounded preparation. What a quality provider adds is clinical guidance on dose titration, side effect management, and long-term treatment strategy.

Where Hims Has the Edge

Where Sequence Has the Edge

Shared Limitations of Both Platforms

How Trimi Differs from Both

For patients who want compounded GLP-1 medication with quality clinical support, Trimi offers a different model from both Hims and Sequence. Trimi charges $99 per month for compounded semaglutide and $125 per month for compounded tirzepatide without promotional codes or limited-time offers; compounded medications are not FDA-approved.

For patients considering switching from either platform, our guides on canceling Hims weight loss and canceling Sequence walk through the transition process step by step.

The Bottom Line

The Hims versus Sequence comparison is a trade-off between a broad multi-category platform and a weight-management program, now WW Med+ through WeightWatchers Clinic. Hims delivers an efficient GLP-1 prescription service backed by the stability of a publicly traded company. WW Med+ pairs the WeightWatchers program with medical services through WeightWatchers Clinic and, as of October 2026, prescribes only FDA-approved medications. Both are legitimate providers prescribing real medications through licensed clinicians.

Trimi offers a third option: compounded semaglutide at $99 per month and compounded tirzepatide at $125 per month, with no consultation fees, no membership fee, and providers who specialize in metabolic health. Compounded medications are not FDA-approved.

The medication produces the results, not the telehealth brand on the shipping label. Choose the provider that gives you the best combination of affordable pricing, clinical support, and treatment flexibility for the long term. We encourage patients to verify current pricing directly on each platform's website and compare total annual cost at your expected maintenance dose, not introductory prices at the lowest tier. For a broader view of the GLP-1 provider landscape, see our cheapest GLP-1 injections 2026 guide and our homepage to start your assessment.